Skip to content
Open access

Differential Effectiveness of Adjuvant Endocrine Therapy According to Menopausal Status, Body Mass Index, and Molecular Subtype in Hormone Receptor-Positive Breast Cancer

Aug 2026 · Journal of Breast Cancer · Vol 29, pp. 389 - 394 · 0 citations · 10 references
Medicine

TL;DR

The association between adjuvant endocrine therapy and BC-specific mortality differed according to menopausal status, BMI, and molecular subtype, suggesting that menopausal status, BMI, and molecular subtype are important considerations when evaluating endocrine treatment strategies.

Abstract

The effectiveness of adjuvant endocrine therapy for hormone receptor-positive (HR+) breast cancer (BC) varies according to menopausal status, body mass index (BMI), and tumor biology. We evaluated the association between selective estrogen receptor modulators (SERMs), aromatase inhibitors (AIs), and BC-specific mortality according to menopausal status, BMI, and molecular subtype in a nationwide Korean cohort. We analyzed data from 31,030 patients with HR+ BC who were registered in the Korean Breast Cancer Society Registry, diagnosed between 2000 and 2008, and followed through 2013. Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for BC-specific mortality after adjusting for demographic and clinical factors. Of the 31,030 patients, 19,634 received SERM therapy, and 3,354 received AI therapy. SERM use was associated with lower BC-specific mortality in premenopausal women (HR, 0.75; 95% CI, 0.63–0.91), whereas AI therapy was more strongly associated with lower BC-specific mortality among postmenopausal women (HR, 0.76; 95% CI, 0.61–0.94). Lower BC-specific mortality was observed among patients with a BMI ≥ 23 kg/m2 who received SERM (HR, 0.84; 95% CI, 0.72–0.98) or AI therapy (HR, 0.78; 95% CI, 0.62–0.99). The strongest association with lower BC-specific mortality was observed in postmenopausal women with luminal B tumors (HR, 0.59; 95% CI, 0.42–0.83). The association between adjuvant endocrine therapy and BC-specific mortality differed according to menopausal status, BMI, and molecular subtype. These findings suggest that menopausal status, BMI, and molecular subtype are important considerations when evaluating endocrine treatment strategies.

Read PDF

Similar papers

Open access Sep 2026

Endocrine therapy adherence and 10-year cardiometabolic risk in hormone receptor-positive breast cancer.

BACKGROUND Adjuvant endocrine therapy (AET) reduces breast cancer (BC) recurrence but may adversely affect cardiometabolic health. We evaluated the association between AET adherence duration and 10-year risk of hypertension, dyslipidemia, diabetes, and mortality among postmenopausal women with early-stage hormone recep...

J. R. Ledesma, Joshua R. Nugent, R. Cheng et al. · 0 citations
Review Open access Sep 2026

The effect of adding ovarian function suppression to adjuvant endocrine therapy in premenopausal patients with hormone receptor-positive, HER2-positive breast cancer who have undergone neoadjuvant therapy: a single-center experience

The role of ovarian function suppression (OFS) in premenopausal patients with hormone receptor (HR)-positive, HER2-positive breast cancer remains unclear in the era of anti-HER2 therapy. This study evaluated the effect of adding OFS to adjuvant endocrine therapy on outcomes in premenopausal patients receiving neoadjuva...

Okan Aydın, Hale Gülçin Yıldırım Doğan, Şermin Dinç Sonuşen et al. · 0 citations
Review Open access Sep 2026

Baseline and Early On-Treatment Prognostic Nutritional Index in Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer Treated with CDK4/6 Inhibitors

Background/Objectives: The prognostic nutritional index (PNI) has been associated with outcome in metastatic breast cancer, but studies in CDK4/6 inhibitor-treated patients have used cohort-derived thresholds and examined only the pretreatment value. We assessed the PNI as a continuous variable, compared it with inflam...

E. Çoban, A. Kurt, Fırat Akagündüz et al. · 0 citations
Review Open access Aug 2026

Endocrine therapy in early-stage estrogen Receptor-Low breast cancer: a systematic review and Meta-Analysis.

BACKGROUND Tumors with ≥1% estrogen receptor (ER) expression by immunohistochemistry (IHC) are classified as hormone receptor-positive. While this definition includes ER-low tumors (ER 1-9%), the clinical benefit of endocrine therapy (ET) in ER-low early-stage breast cancer (BC) remains uncertain. METHODS This is a s...

D. Massa, E. Chiappe, V. Delucchi et al. · 0 citations
Open access Aug 2026

CA 15.3, Metastatic Burden, and Overall Survival in Hormone Receptor-Positive/HER2-Negative Advanced Breast Cancer: Real-World Evidence from Peru

Elevated baseline CA 15.3 was associated with greater metastatic burden and shorter OS, and baseline/follow-up patterns were exploratory because the sampling was not standardized, and should be interpreted as an adjunct to clinical and radiological assessment.

Guillermo Valencia, P. Rioja, Jessica Meza et al. · 0 citations
Open access Aug 2026

Risk Factors for Estrogen Receptor Subtype-Specific Contralateral Breast Cancer in Women Under Age 55 Years

Women with estrogen receptor negative (ER-) contralateral breast cancer (CBC) are 50% more likely to die of CBC compared to women with estrogen receptor positive (ER+) CBC. We comprehensively investigated risk factors for ER subtype-specific CBC using the Women’s Environmental Cancer and Radiation Epidemiology Study, a...

Anne S. Reiner, K. Malone, Charles F. Lynch et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.